119. Special Edition: Quiet Leader, Loud Results, Ankit Mahadevia, Author

119. Special Edition: Quiet Leader, Loud Results, Ankit Mahadevia, Author

Interested in purchasing the book? Order here: https://amzn.to/3R4RWfT Ankit Mahadevia is the founder and CEO of Spero Therapeutics, an organization committed to fighting the threat of infectious disease through the development of novel medicines. Over his career, he has led the formation of nine companies, including Spero, several of which are trading on the Nasdaq exchange and several others acquired by large pharmaceutical organizations. Through these companies, he has raised over $1 billion for the development of novel therapeutics, and built multiple high performing management teams. He and the companies he built have won multiple awards for their culture, including Boston Business Journal’s “Best Places to Work” Award and Glassdoor’s “Top 50 CEOs of 2021” (#15 nationwide). Prior to these roles, Ankit advised on and supported investments in the biotechnology sector as a Venture Partner at Atlas Venture, a Cambridge, MA venture capital firm. He held previous positions at organizations including Genentech, McKinsey & Company, the United States Government Accountability Office, and the U.S. Senate Health, Education, Labor, and Pensions Committee. He has spoken widely on entrepreneurship and leadership, including at Harvard University, Columbia University, Northwestern University, MIT, and the Berkeley Forum. Ankit received his medical degree from the Johns Hopkins University School of Medicine, an MBA from the Wharton School at the University of Pennsylvania, and a BA from Northwestern University. He lives in Chestnut Hill, MA with his wife and two sons.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(261)

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Juni 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Maj 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Apr 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Mars 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Mars 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Feb 25min

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and...

10 Feb 26min

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world’s largest privately held pharma companies, Brian Hilberdink’s journey is anything but conventional. Li...

28 Jan 21min

Populärt inom Vetenskap

p3-dystopia
dumma-manniskor
allt-du-velat-veta
kapitalet-en-podd-om-ekonomi
medicinvetarna
svd-nyhetsartiklar
bildningspodden
det-morka-psyket
rss-ufobortom-rimligt-tvivel
rss-spraket
rss-vetenskapsradion
rss-vetenskapsradion-2
sexet
rss-broccolipodden-en-podcast-som-inte-handlar-om-broccoli
rss-kriminologerna
dumforklarat
rss-arkeologi-historia-podden-som-graver-i-vart-kulturlandskap
vetenskapsradion
rss-lara-fran-larda-en-fackbok-och-en-forfattare
doden-hjarnan-kemisten